Publications

Complete List of my Publications:

https://scholar.google.com/citations?user=uY6L-3YAAAAJ&hl=en

1. Wang, X., Li, J., Zhu, Y., Shen, H., Ding, J., Zeng, T., Min, W., Liang, S.-Q., Huang, L., Shi, Z., Shen, H., Huang, F., Yuan, K., Kuang, W., Ji, M., Sun, C., Hou, Y., Wang, L., Chen, W., Jiang, Y., Hao, H., Xiao, Y., Yang, P. (2025). Targeting ADAR1 with a small molecule for the treatment of prostate cancer. Nature Cancer.  doi: 10.1038/s43018-025-00907-4

2. Shi, Z., Li, J., Ding, J., Zhang, Y., Min, W., Zhu, Y., Hou, Y., Yuan, K., Sun, C., Wang, X., Shen, H., Wang, L., Liang, S.-Q. (Corresponding Author), Kuang, W., Wang, X., Yang, P. (2024). ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis. Leukemia.  doi: 10.1038/s41375-024-02500-7

3. Xu*, D., Liang*, S.-Q., Su, M., Yang, H., Bruggmann, R., Oberhaensli, S., Yang, Z., Gao, Y., Marti, T. M., Wang, W., Schmid, R. A., Shu, Y., Dorn, P., Peng, R.-W. (2024). Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesothelioma. Lung Cancer, 197, 107986.  doi: 10.1016/j.lungcan.2024.107986 

4. Liang, S.-Q., Navia, A. W., Ramseier, M., Zhou, X., Martinez, M., Lee, C., Zhou, C., Wu, J., Xie, J., Su, Q., Wang, D., Flotte, T. R., Anderson, D. G., Tarantal, A. F., Shalek, A. K., Gao, G., Xue, W. (2024). AAV5 Delivery of CRISPR/Cas9 Mediates Genome Editing in the Lungs of Young Rhesus Monkeys. Human Gene Therapy, 35(19-20), 814-824.  doi: 10.1089/hum.2024.035 

5. Liang, S.-Q. (Corresponding Author), Xue, W. (Corresponding Author) (2024). All types of base conversions allowed by base editors. Science China Life Sciences. 

6. Chen, Z., Kwan, S.-Y., Mir, A., Hazeltine, M., Shin, M., Liang, S.-Q., Chan, I. L., Kelly, K., Ghanta, K. S., Gaston, N., Cao, Y., Xie, J., Gao, G., Xue, W., Sontheimer, E. J., Watts, J. K. (2023). A Fluorescent Reporter Mouse for In Vivo Assessment of Genome Editing with Diverse Cas Nucleases and Prime Editors. The CRISPR Journal, 6(6), 570-582.  doi: 10.1089/crispr.2023.0048

7. Li*, B., Manan*, R. S., Liang*, S.-Q., Gordon, A., Jiang, A., Varley, A., Gao, G., Langer, R., Xue, W., Anderson, D. (2023). Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nature Biotechnology, 41(10), 1410-1415.  doi: 10.1038/s41587-023-01679-x

8. Liang, S.-Q., Liu, P., Ponnienselvan, K., Suresh, S., Chen, Z., Kramme, C., Chatterjee, P., Zhu, L. J., Sontheimer, E. J., Xue, W., Wolfe, S. A. (2023). Genome-wide profiling of prime editor off-target sites in vitro and in vivo using PE-tag. Nature Methods, 20(6), 898-907.  doi: 10.1038/s41592-023-01859-2

9. Liang, S.-Q., Wolfe, S. (2023). Capturing prime editor off-target sites within the genome. Nature Methods. 

10. Yang, H., Gao, Y., Xu, D., Xu, K., Liang, S.-Q., Yang, Z., Scherz, A., Hall, S. R., Forster, S., Berezowska, S., Yao, F., Ochsenbein, A. F., Marti, T. M., Kocher, G. J., Schmid, R. A., Dorn, P., Peng, R.-W. (2023). MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell Death Discovery, 9(1).  doi: 10.1038/s41420-023-01307-2

11. Liu, B., Dong, X., Cheng, H., Zheng, C., Chen, Z., Rodríguez, T. C., Liang, S.-Q., Xue, W., Sontheimer, E. J. (2022). A split prime editor with untethered reverse transcriptase and circular RNA template. Nature Biotechnology, 40(9), 1388-1393.  doi: 10.1038/s41587-022-01255-9

12. Zheng, C., Liang, S.-Q., Liu, B., Liu, P., Kwan, S.-Y., Wolfe, S. A., Xue, W. (2022). A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Molecular Therapy, 30(3), 1343-1351.  doi: 10.1016/j.ymthe.2022.01.005

13. Liang, S.-Q., Walkey, C. J., Martinez, A. E., Su, Q., Dickinson, M. E., Wang, D., Lagor, W. R., Heaney, J. D., Gao, G., Xue, W. (2022). AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway. Molecular Therapy, 30(1), 238-243.  doi: 10.1016/j.ymthe.2021.10.023

14. Liang, S.-Q., Liu, P., Smith, J. L., Mintzer, E., Maitland, S., Dong, X., Yang, Q., Lee, J., Haynes, C. M., Zhu, L. J., Watts, J. K., Sontheimer, E. J., Wolfe, S. A., Xue, W. (2022). Genome-wide detection of CRISPR editing in vivo using GUIDE-tag. Nature Communications, 13(1).  doi: 10.1038/s41467-022-28135-9

15. Yang*, Z., Liang*, S.-Q., Zhao, L., Yang, H., Marti, T. M., Hegedüs, B., Gao, Y., Zheng, B., Chen, C., Wang, W., Dorn, P., Kocher, G. J., Schmid, R. A., Peng, R.-W. (2022). Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. Journal of Experimental & Clinical Cancer Research, 41(1).  doi: 10.1186/s13046-022-02240-5

16. Yang*, Z., Liang*, S.-Q., Saliakoura, M., Yang, H., Vassella, E., Konstantinidou, G., Tschan, M., Hegedüs, B., Zhao, L., Gao, Y., Xu, D., Deng, H., Marti, T. M., Kocher, G. J., Wang, W., Schmid, R. A., Peng, R.-W. (2021). Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer. EMBO Molecular Medicine, 13(9).  doi: 10.15252/emmm.202013193

17. Yang*, Z., Liang*, S.-Q., Yang, H., Xu, D., Bruggmann, R., Gao, Y., Deng, H., Berezowska, S., Hall, S. R.R., Marti, T. M., Kocher, G. J., Zhou, Q., Schmid, R. A., Peng, R.-W. (2021). CRISPR-mediated kinome editing prioritizes a synergistic combination therapy for FGFR1-amplified lung cancer. Cancer Research, 81(11), 3121-3133.  doi: 10.1158/0008-5472.CAN-20-2276

18. Xu, D., Liang*, S.-Q., Yang, Z., Yang, H., Bruggmann, R., Oberhaensli, S., Berezowska, S., Marti, T. M., Hall, S. R., Dorn, P., Kocher, G. J., Schmid, R. A., Peng, R.-W. (2021). Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell Death & Disease, 12(4).  doi: 10.1038/s41419-021-03668-x

19. Liu, P., Liang*, S.-Q., Zheng, C., Mintzer, E., Zhao, Y. G., Ponnienselvan, K., Mir, A., Sontheimer, E. J., Gao, G., Flotte, T. R., Wolfe, S. A. (Corresponding Author), Xue, W. (Corresponding Author) (2021). Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nature Communications.  doi: https://doi.org/10.1038/s41467-021-22295-w

20. Smith, J. L., Rodríguez, T. C., Mou, H., Kwan, S., Pratt, H., Zhang, X., Cao, Y., Liang, S.-Q., Ozata, D. M., Yu, T., Yin, Q., Hazeltine, M., Weng, Z., Sontheimer, E. J., Xue, W. (2021). YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte‐Like Cells. Hepatology, 73(3), 1011-1027.  doi: 10.1002/hep.31389

21. Xu, D., Liang*, S.-Q., Yang, H., Bruggmann, R., Berezowska, S., Yang, Z., Marti, T. M., Hall, S. R., Gao, Y., Kocher, G. J., Schmid, R. A., Peng, R.-W. (2020). CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Molecular Cancer Therapeutics, 19(2), 661-672.  doi: 10.1158/1535-7163.mct-19-0724

22. Lee, J., Mou, H., Ibraheim, R., Liang, S.-Q., Liu, P., Xue, W., Sontheimer, E. J. (2019). Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins. RNA, 25(11), 1421-1431.  doi: 10.1261/rna.071704.119

23. Xu, D., Yang, H., Yang, Z., Berezowska, S., Gao, Y., Liang, S.-Q., Marti, T. M., Hall, S. R., Dorn, P., Kocher, G. J., Schmid, R. A., Peng, R.-W. (2019). Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers, 11(10), 1502.  doi: 10.3390/cancers11101502

24. Yang, H., Liang, S.-Q., Schmid, R. A., Peng, R.-W. (2019). New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Frontiers in Oncology, 9.  doi: 10.3389/fonc.2019.00953

25. Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., Peng, R.-W. (2019). HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis, 8(9).  doi: 10.1038/s41389-019-0158-7

26. Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R., Vassella, E., Yang, Z., Kocher, G. J., Amrein, M. A., Riether, C., Ochsenbein, A. F., Schmid, R. A., Peng, R.-W. (2019). mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene, 38(5), 622-636.  doi: 10.1038/s41388-018-0479-6

27. Yang, H., Xu, J., Yao, F., Liang, S.-Q., Zhao, H. (2018). Analysis of unexpected small cell lung cancer following surgery as the primary treatment. Journal of Cancer Research and Clinical Oncology, 144(12), 2441-2447.  doi: 10.1007/s00432-018-2766-6

28. Xu, D., Liang, S.-Q., Yang, H., Lüthi, U., Riether, C., Berezowska, S., Marti, T. M., Hall, S. R., Bruggmann, R., Kocher, G. J., Schmid, R. A., Peng, R.-W. (2018). Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. British Journal of Cancer, 119(1), 65-75.  doi: 10.1038/s41416-018-0145-3

29. Liang, S.-Q., Marti, Dorn, Froment, Hall, Berezowska, Kocher, Schmid, Peng (2016). Epithelial-to-mesenchymal transition (EMT) is required for resistance to anti-folate chemotherapy in lung cancer. Journal of Thoracic Oncology, 11(4).  doi: 10.1016/S1556-0864(16)30132-0

30. Liang, S.-Q., Marti, Dorn, Froment, Hall, Berezowska, Kocher, Schmid, Peng (2015). Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer. Cell Death and Disease, 6(7).  doi: 10.1038/cddis.2015.195

31. Liang, S.-Q., Wu, H., Liu, B., Xiao, J., Wang, Q., Zhang, Y. (2012). Immune response of turbot (Scophthalmus maximus L.) to a broad spectrum vaccine candidate, recombinant glyceraldehyde-3-phosphate dehydrogenase of Edwardsiella tarda. Veterinary Immunology and Immunopathology, 150(3-4), 198-205.  doi: 10.1016/j.vetimm.2012.09.036

32. Li, Wu, Zhang, Liang, S.-Q., Xiao, Wang, Liu, Zhang (2012). Secreted glyceraldehyde-3-phosphate dehydrogenase as a broad spectrum vaccine candidate against microbial infection in aquaculture. Letters in Applied Microbiology, 54(1), 1-9.  doi: 10.1111/j.1472-765X.2011.03164.x